课题基金 / 基金详情

Function of CXCR2 signalling within the articular cartilage

Function of CXCR2 signalling within the articular cartilage
CXCR2 信号在关节软骨内的功能
批准号:
MR/N010973/1
负责人:
Francesco Dell'Accio
金额:
$61.88万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2016
资助国家:
英国
项目状态:
已结题
起止时间:
2016 至 --

项目摘要

项目成果

Francesco Dell'Accio的其他基金

相似基金

相关文献

中文摘要
翻译
腕骨是覆盖我们长骨末端的组织,允许我们的关节无摩擦地运动。这种组织在骨关节炎期间丢失(降解),导致关节疼痛和无法行走或执行简单任务。骨关节炎是英国残疾津贴的主要原因;它影响超过三分之一的50岁以上人口,因此是影响福祉的主要因素,特别是在老年人中。迄今为止,我们没有任何治疗方法可以阻止骨关节炎的进展,唯一的补救措施是止痛药和关节置换。虽然关节置换术通常有效,但在约20%的病例中,关节置换术达不到患者的期望,并且寿命有限,通常需要复杂且具有挑战性的翻修手术(成功率低)。关节置换术的这些严重局限性变得更加突出,因为人们的寿命更长,并且因为更多的人在年轻时患上骨关节炎(例如,由于肥胖或运动损伤)。损伤后,软骨响应以保持其完整性,然而,当这种响应不足时,软骨破裂进展。令人兴奋的是,最近的数据表明,支持这些内在的保护性反应在动物模型中可以非常成功,防止软骨破坏,甚至再生受损组织。我们已经发现称为ELR+CXC趋化因子的分子参与了这些保护性反应。以前已知的吸引免疫细胞到炎症部位,我们已经发现,当存在于健康软骨中时,这些分子具有完全不同的作用,支持损伤后的软骨完整性。因此,被设计成缺乏这种保护性反应的小鼠更容易患实验性骨关节炎。我们发现ELR+CXC趋化因子保留在软骨组织中,因为它们与称为HSPG的复杂糖分子结合。因此,软骨中存在的ELR+CXC趋化因子不能吸引炎性细胞,而是帮助软骨保持健康并从轻微损伤中恢复。在骨关节炎期间,当软骨严重受损时,ELR+CXC趋化因子从组织中丢失,因此它们不再能保护软骨,它们也可能直接导致炎症。在这项研究中,我们打算回答以下问题:1)这些趋化因子在骨关节炎期间究竟如何保护软骨?为了做到这一点,我们将建立一个小鼠模型,使我们能够将趋化因子对软骨的影响与对关节功能和炎症的其他方面的影响分开。重要的是,它还将提供信息,在骨关节炎的发展过程中,这些分子的功能,这是必不可少的,如果我们要利用这种保护活性的治疗应用。2)什么是最有效的ELR+CXC趋化因子,以支持软骨健康?有不同的ELR+CXC趋化因子,有数据表明,一些可能比其他更好地支持软骨完整性。确定最好的趋化因子是非常重要的治疗应用。3)我们可以修改趋化因子,使他们成为无法吸引炎症细胞,但保留其能力,以保护软骨?我们将通过改变它们与HSPGs结合的方式来实现这一目标,这样它们就不能粘附在血管上,从而招募炎症细胞。4)我们将构建一种含有并保留ELR+CXC趋化因子的生物材料,以测试组织工程修复/保护软骨而不引起炎症的潜力。修复骨关节炎中的软骨:这是导致残疾的主要原因,我们仍然没有治愈方法。
英文摘要
Cartilage is the tissue that covers the ends of our long bones, allowing the frictionless motion of our joints. This tissue is lost (degraded) during osteoarthritis, leading to joint pain and incapacity to walk or perform simple tasks. Osteoarthritis is the leading cause for disability allowance in the UK; it affects greater than 1 in 3 of the population over the age of 50 and therefore is a major factor affecting well-being, particularly in the elderly. To-date, we do not have any treatment that stops progression of osteoarthritis and the only remedies are pain killers and joint replacement. Although generally effective, joint replacement does not live up to patients' expectations in ~20% of cases, and has a limited life span often requiring complex and challenging revision surgery (with a poor success rate). These serious limitations of joint replacement are becoming more prominent due to the fact that people live much longer and because more people are developing osteoarthritis at a younger age (e.g. due to obesity, or following sports injuries). Following injury, cartilage responds to maintain its integrity, however, cartilage breakdown progresses when this response is insufficient. Excitingly, recent data have shown that supporting these intrinsic protective responses can be very successful in animal models, preventing cartilage breakdown and even regenerating damaged tissue. We have discovered that molecules called ELR+CXC chemokines are involved in these protective responses. Previously known for attracting immune cells to sites of inflammation, we have discovered that, when present within healthy cartilage, these molecules have a totally different role supporting cartilage integrity following injury. As a consequence, mice that have been engineered to lack this protective response are more susceptible to experimental osteoarthritis. We discovered that ELR+CXC chemokines are retained in the cartilage tissue because they are bound to complex sugar molecules called HSPGs. Therefore, ELR+CXC chemokines present in cartilage cannot attract inflammatory cells and, instead, help cartilage to stay healthy and recover from minor injury. When, during osteoarthritis, cartilage becomes badly damaged, ELR+CXC chemokines are lost from the tissue so that they can no longer protect cartilage and they may also contribute directly to inflammation.In this study we intend to answer the following questions: 1) How exactly do these chemokines protect cartilage during osteoarthritis? To do this we will make a mouse model that will enable us to separate the effects of chemokines on cartilage from those on other aspects of joint function and inflammation. Importantly, it will also provide information on which point during the development of osteoarthritis these molecules function, which is essential if we are to harness this protective activity for therapeutic applications.2) What is the most potent ELR+CXC chemokine to support cartilage health? There are different ELR+CXC chemokines and there is data to suggest that some may be better than others at supporting cartilage integrity. Identifying the best chemokine is very important for therapeutic applications.3) Can we modify chemokines so that they become unable of attracting inflammatory cells and yet retain their capacity to protect cartilage? We will achieve this by modifying the way they bind to HSPGs so that they cannot adhere to blood vessels where they would recruit inflammatory cells.4) We will build a biomaterial containing and retaining ELR+CXC chemokines to test the potential of tissue engineering to repair/protect cartilage without causing inflammation.This project develops from our discovery of this unexpected function of chemokines and identifies a way we can protect/repair cartilage in osteoarthritis: a leading cause of disability for which we still do not have a cure.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1073/pnas.2211631120
发表时间: 2023-04-25
期刊: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
影响因子: 11.1
作者: [Caxaria, Sara, Bharde, Sabah, Fuller, Alice M., Evans, Romy, Thomas, Bethan, Celik, Petek, Dell'Accio, Francesco, Yona, Simon, Gilroy, Derek, Voisin, Mathieu-Benoit, Wood, John N., Sikandar, Shafaq]
通讯作者: Sikandar, Shafaq
WNT16 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis.
WNT16拮抗过多的典型WNT激活,并保护骨关节炎的软骨。
DOI: 10.1136/annrheumdis-2015-208577
发表时间: 2017-01
期刊: Annals of the rheumatic diseases
影响因子: 27.4
作者: [Nalesso G, Thomas BL, Sherwood JC, Yu J, Addimanda O, Eldridge SE, Thorup AS, Dale L, Schett G, Zwerina J, Eltawil N, Pitzalis C, Dell'Accio F]
通讯作者: Dell'Accio F
DOI: 10.15252/emmm.202216218
发表时间: 2023-01-11
期刊: EMBO molecular medicine
影响因子: 11.1
作者: []
通讯作者:
The Role of CXCl6 in Cartilage Development and Homeostasis
CXCl6 在软骨发育和稳态中的作用
DOI: 10.1016/j.joca.2017.02.507
发表时间: 2017
期刊: Osteoarthritis and Cartilage
影响因子: 7
作者: [Caxaria S]
通讯作者: Caxaria S
共 6 条
    Agrin, a unique growth factor for cartilage regeneration in osteoarthritis
    • 批准号:
      MR/R000956/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $60.48万
    • 财政年份:
      2018
    • 负责人:
      Francesco Dell'Accio
    • 依托单位:
    Targeting WNT/CaMKII in Osteoarthritis
    • 批准号:
      MR/K013076/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $38.64万
    • 财政年份:
      2013
    • 负责人:
      Francesco Dell'Accio
    • 依托单位:
    国内基金
    海外基金
    ETV4乳酸化驱动CXCL5/CXCR2轴介导微卫星稳定型结直肠癌免疫治疗耐药的机制研究
    • 批准号:
      82560608
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      32.00万元
    • 批准年份:
      2025
    • 负责人:
      武涛
    • 依托单位:
    CXCR2/Neutrophils/IL6正反馈轴在NAT10高表达结直肠癌促进神经生长中的作用机制研究
    • 批准号:
      82560504
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      32.00万元
    • 批准年份:
      2025
    • 负责人:
      程先硕
    • 依托单位:
    CXCL2+中性粒细胞通过CXCR2/MMP12调控 巨噬细胞在促放射性肺纤维化中的作用 及机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2025
    • 负责人:
      谭佩欣
    • 依托单位:
    肝细胞CXCR2介导SREBP-1c“乳酸化—泛素化”修饰串扰参与MASLD进展的机制研究
    • 批准号:
      82500710
    • 项目类别:
      青年科学基金项目(C类)
    • 资助金额:
      30.00万元
    • 批准年份:
      2025
    • 负责人:
      王威
    • 依托单位: